Kyle RA, Rajkumar SV: Multiple myeloma. N Engl J Med. 2004, 351: 1860-1873. 10.1056/NEJMra041875.
Article
CAS
PubMed
Google Scholar
Naumann F, Weingart O, Kruse E, Schulz H, Bohlius J, Hulsewede H, Engert A: Fifth biannual report of the cochrane haematologic malignancies group--focus on multiple myeloma. J Natl Cancer Inst. 2006, 98: E2-E. 10.1093/jnci/djj328.
Article
PubMed
Google Scholar
Robak T, Korycka A, Kasznicki M, Wrzesien-Kus A, Smolewski P: Purine nucleoside analogues for the treatment of hematological malignancies: pharmacology and clinical applications. Curr Cancer Drug Targets. 2005, 5 (6): 421-444. 10.2174/1568009054863618.
Article
CAS
PubMed
Google Scholar
Robak T, Lech-Maranda E, Korycka A, Robak E: Purine nucleoside analogs as immunosuppressive and antineoplastic agents: mechanism of action and clinical activity. Curr Med Chem. 2006, 13: 3165-3189. 10.2174/092986706778742918.
Article
CAS
PubMed
Google Scholar
Hjertner O, Borset M, Waage A: Comparison of the effects of 2-chlorodeoxyadenosine and melphalan on myeloma cell lines. Leuk Res. 1996, 20: 155-160. 10.1016/0145-2126(95)00128-X.
Article
CAS
PubMed
Google Scholar
Gidron A, Tallman MS: 2-CdA in the treatment of hairy cell leukemia: a review of long-term follow-up. Leuk Lymphoma. 2006, 47 (11): 2301-2307. 10.1080/10428190600822052.
Article
CAS
PubMed
Google Scholar
Huynh E, Sigal D, Saven A: Cladribine in the treatment of hairy cell leukemia: initial and subsequent results. Leuk Lymphoma. 2009, 50 (Suppl 1): 12-17.
Article
CAS
PubMed
Google Scholar
Chadha P, Rademaker AW, Mendiratta P, Kim B, Evanchuk DM, Hakimian D, Peterson LC, Tallman MS: Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA): long-term follow-up of the Northwestern University experience. Blood. 2005, 106: 241-246. 10.1182/blood-2005-01-0173.
Article
CAS
PubMed
Google Scholar
Cheson BD, Sorensen JM, Vena DA, Montello MJ, Barrett JA, Damasio E, Tallman M, Annino L, Connors J, Coiffier B, Lauria F: Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine via the Group C protocol mechanism of the National Cancer Institute: a report of 979 patients. J Clin Oncol. 1998, 16: 3007-3015.
CAS
PubMed
Google Scholar
Jehn U, Bartl R, Dietzfelbinger H, Haferlach T, Heinemann V: An update: 12-year follow-up of patients with hairy cell leukemia following treatment with 2-chlorodeoxyadenosine. Leukemia. 2004, 18: 1476-1481. 10.1038/sj.leu.2403418.
Article
CAS
PubMed
Google Scholar
Bertazzoni P, Rabascio C, Gigli F, Calabrese L, Radice D, Calleri A, Gregato G, Negri M, Liptrott SJ, Bassi S, Nassi L, Sammassimo S, Laszlo D, Preda L, Pruneri G, Orlando L, Martinelli G: Rituximab and subcutaneous cladribine in chronic lymphocytic leukemia for newly diagnosed and relapsed patients. Leuk Lymphoma. 2010, 51: 1485-1493. 10.3109/10428194.2010.495799.
Article
CAS
PubMed
Google Scholar
Leupin N, Schuller JC, Solenthaler M, Heim D, Rovo A, Beretta K, Gregor M, Bargetzi MJ, Brauchli P, Himmelmann A, Hanselmann S, Zenhäusern R: Efficacy of rituximab and cladribine in patients with chronic lymphocytic leukemia and feasibility of stem cell mobilization: a prospective multicenter phase II trial (protocol SAKK 34/02). Leuk Lymphoma. 2010, 51: 613-619. 10.3109/10428191003624231.
Article
CAS
PubMed
Google Scholar
Sigal DS, Miller HJ, Schram ED, Saven A: Beyond hairy cell: the activity of cladribine in other hematologic malignancies. Blood. 2010, 116: 2884-2896. 10.1182/blood-2010-02-246140.
Article
CAS
PubMed
Google Scholar
Dimopoulos MA, Kantarjian H, Estey E, O'Brien S, Delasalle K, Keating MJ, Freireich EJ, Alexanian R: Treatment of Waldenstrom macroglobulinemia with 2-chlorodeoxyadenosine. Ann Intern Med. 1993, 118: 195-198.
Article
CAS
PubMed
Google Scholar
Dimopoulos MA, Kantarjian HM, Estey EH, Alexanian R: 2-Chlorodeoxyadenosine in the treatment of multiple myeloma. Blood. 1992, 80: 1626-
CAS
PubMed
Google Scholar
Niesvizky R, Siegel D, Michaeli J: 2-Chlorodeoxyadenosine for multiple myeloma. Blood. 1993, 81: 868-869.
CAS
PubMed
Google Scholar
Niesvizky R, Siegel D, Michaeli J: Biology and treatment of multiple myeloma. Blood Rev. 1993, 7: 24-33. 10.1016/0268-960X(93)90021-U.
Article
CAS
PubMed
Google Scholar
Krett NL, Ayres M, Nabhan C, Ma C, Nowak B, Nawrocki S, Rosen ST, Gandhi V: In vitro assessment of nucleoside analogs in multiple myeloma. Cancer Chemother Pharmacol. 2004, 54: 113-121.
Article
CAS
PubMed
Google Scholar
Nagourney RA, Evans SS, Messenger JC, Su YZ, Weisenthal LM: 2 chlorodeoxyadenosine activity and cross resistance patterns in primary cultures of human hematologic neoplasms. Br J Cancer. 1993, 67: 10-14. 10.1038/bjc.1993.3.
Article
CAS
PubMed
PubMed Central
Google Scholar
Bagley RG, Roth S, Kurtzberg LS, Rouleau C, Yao M, Crawford J, Krumbholz R, Lovett D, Schmid S, Teicher BA: Bone marrow CFU-GM and human tumor xenograft efficacy of three antitumor nucleoside analogs. Int J Oncol. 2009, 34: 1329-1340.
Article
CAS
PubMed
Google Scholar
Johnston JB: Mechanism of Action of Pentostatin and Cladribine in Hairy Cell Leukemia. Leuk Lymphoma. 2011
Google Scholar
Chesi M, Bergsagel PL: Epigenetics and microRNAs combine to modulate the MDM2/p53 axis in myeloma. Cancer Cell. 2010, 18: 299-300. 10.1016/j.ccr.2010.10.004.
Article
CAS
PubMed
Google Scholar
Pichiorri F, Suh SS, Rocci A, De Luca L, Taccioli C, Santhanam R, Zhou W, Benson DM, Hofmainster C, Alder H, et al: Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development. Cancer Cell. 2010, 18: 367-381. 10.1016/j.ccr.2010.09.005.
Article
CAS
PubMed
PubMed Central
Google Scholar
Burger R, Bakker F, Guenther A, Baum W, Schmidt-Arras D, Hideshima T, Tai YT, Shringarpure R, Catley L, Senaldi G, Gramatzki M, Anderson KC: Functional significance of novel neurotrophin-1/B cell-stimulating factor-3 (cardiotrophin-like cytokine) for human myeloma cell growth and survival. Br J Haematol. 2003, 123: 869-878. 10.1046/j.1365-2141.2003.04686.x.
Article
CAS
PubMed
Google Scholar
Catlett-Falcone R, Landowski TH, Oshiro MM, Turkson J, Levitzki A, Savino R, Ciliberto G, Moscinski L, Fernandez-Luna JL, Nunez G, Dalton WS, Jove R: Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity. 1999, 10: 105-115. 10.1016/S1074-7613(00)80011-4.
Article
CAS
PubMed
Google Scholar
Hodge DR, Xiao W, Wang LH, Li D, Farrar WL: Activating mutations in STAT3 and STAT5 differentially affect cellular proliferation and apoptotic resistance in multiple myeloma cells. Cancer Biol Ther. 2004, 3: 188-194.
Article
CAS
PubMed
Google Scholar
Al Zaid Siddiquee K, Turkson J: STAT3 as a target for inducing apoptosis in solid and hematological tumors. Cell Res. 2008, 18: 254-267. 10.1038/cr.2008.18.
Article
CAS
PubMed
Google Scholar
Lee CK, Wang S, Huang X, Ryder J, Liu B: HDAC inhibition synergistically enhances alkylator-induced DNA damage responses and apoptosis in multiple myeloma cells. Cancer Lett. 2010, 296: 233-240. 10.1016/j.canlet.2010.04.014.
Article
CAS
PubMed
PubMed Central
Google Scholar
Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C, Darnell JE: Stat3 as an oncogene. Cell. 1999, 98: 295-303. 10.1016/S0092-8674(00)81959-5.
Article
CAS
PubMed
Google Scholar
Yu H, Jove R: The STATs of cancer--new molecular targets come of age. Nat Rev Cancer. 2004, 4: 97-105. 10.1038/nrc1275.
Article
CAS
PubMed
Google Scholar
Yue P, Turkson J: Targeting STAT3 in cancer: how successful are we?. Expert Opin Investig Drugs. 2009, 18: 45-56. 10.1517/13543780802565791.
Article
CAS
PubMed
PubMed Central
Google Scholar
Siddiquee K, Zhang S, Guida WC, Blaskovich MA, Greedy B, Lawrence HR, Yip ML, Jove R, McLaughlin MM, Lawrence NJ, et al: Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity. Proc Natl Acad Sci USA. 2007, 104: 7391-7396. 10.1073/pnas.0609757104.
Article
CAS
PubMed
PubMed Central
Google Scholar
Liliemark J, Juliusson G: On the pharmacokinetics of 2-chloro-2'-deoxyadenosine in humans. Cancer Res. 1991, 51: 5570-5572.
CAS
PubMed
Google Scholar
Sonderegger T, Betticher DC, Cerny T, Lauterburg BH: Pharmacokinetics of 2-chloro-2'-deoxyadenosine administered subcutaneously or by continuous intravenous infusion. Cancer Chemother Pharmacol. 2000, 46: 40-42. 10.1007/s002800000129.
Article
CAS
PubMed
Google Scholar
Hideshima T, Mitsiades C, Tonon G, Richardson PG, Anderson KC: Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer. 2007, 7: 585-598. 10.1038/nrc2189.
Article
CAS
PubMed
Google Scholar
Podar K, Chauhan D, Anderson KC: Bone marrow microenvironment and the identification of new targets for myeloma therapy. Leukemia. 2009, 23: 10-24. 10.1038/leu.2008.259.
Article
CAS
PubMed
Google Scholar
Edwards A, Li J, Atadja P, Bhalla K, Haura EB: Effect of the histone deacetylase inhibitor LBH589 against epidermal growth factor receptor-dependent human lung cancer cells. Mol Cancer Ther. 2007, 6: 2515-2524. 10.1158/1535-7163.MCT-06-0761.
Article
CAS
PubMed
Google Scholar
Lin TY, Fenger J, Murahari S, Bear MD, Kulp SK, Wang D, Chen CS, Kisseberth WC, London CA: AR-42, a novel HDAC inhibitor, exhibits biologic activity against malignant mast cell lines via down-regulation of constitutively activated Kit. Blood. 2010, 115: 4217-4225. 10.1182/blood-2009-07-231985.
Article
CAS
PubMed
PubMed Central
Google Scholar
Mitsiades CS, Mitsiades N, Munshi NC, Anderson KC: Focus on multiple myeloma. Cancer Cell. 2004, 6: 439-444. 10.1016/j.ccr.2004.10.020.
Article
CAS
PubMed
Google Scholar
Sprynski AC, Hose D, Caillot L, Reme T, Shaughnessy JD, Barlogie B, Seckinger A, Moreaux J, Hundemer M, Jourdan M, Meissner T, Jauch A, Mahtouk K, Kassambara A, Bertsch U, Rossi JF, Goldschmidt H, Klein B: The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor. Blood. 2009, 113: 4614-4626. 10.1182/blood-2008-07-170464.
Article
CAS
PubMed
PubMed Central
Google Scholar
Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Shringarpure R, Akiyama M, Hideshima T, Chauhan D, Joseph M, Libermann TA, García-Echeverría C, Pearson MA, Hofmann F, Anderson KC, Kung AL: Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell. 2004, 5: 221-230. 10.1016/S1535-6108(04)00050-9.
Article
CAS
PubMed
Google Scholar
Menu E, van Valckenborgh E, van Camp B, Vanderkerken K: The role of the insulin-like growth factor 1 receptor axis in multiple myeloma. Arch Physiol Biochem. 2009, 115: 49-57. 10.1080/13813450902736583.
Article
CAS
PubMed
Google Scholar
Knuefermann C, Lu Y, Liu B, Jin W, Liang K, Wu L, Schmidt M, Mills GB, Mendelsohn J, Fan Z: HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells. Oncogene. 2003, 22: 3205-3212. 10.1038/sj.onc.1206394.
Article
CAS
PubMed
Google Scholar
Wang S, Huang X, Lee CK, Liu B: Elevated expression of erbB3 confers paclitaxel resistance in erbB2-overexpressing breast cancer cells via upregulation of Survivin. Oncogene. 2010, 29: 4225-4236. 10.1038/onc.2010.180.
Article
CAS
PubMed
Google Scholar